Compare AbbVie Inc (ABBV) vs Spotify Technology (SPOT) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Spotify (SPOT) trades at $493.95, up 1.64% with a bullish technical outlook. The stock shows strong fundamentals with revenue growth from $11.7B in 2022 to $17.2B in 2025 and net income turning positive to $2.2B. Analyst consensus is bullish with a $623 price target, supported by recent earnings beats. Key resistance is near $499, while support holds at $477.

Outlook remains positive driven by margin expansion and platform diversification, but risks include competition and market volatility. The stock offers growth potential with a 26% upside to consensus target, though investors should monitor execution on profitability goals amid rising content costs.